CNTX-4975-05 clinical trials
Also written CNTX-4975-05.
How each study uses CNTX-4975-05 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CNTX-4975-05
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Centrexion Therapeutics (3)
Studies
Open first, then newest update. How each study uses CNTX-4975-05 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee PainCompletedPhase 3Centrexion TherapeuticsNCT03429049Written as CNTX-4975-05
- A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee PainCompletedPhase 3Centrexion TherapeuticsNCT03660943Written as CNTX-4975-05
- A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee OsteoarthritisCompletedPhase 1Centrexion TherapeuticsNCT03576508Written as CNTX-4975-05